[go: up one dir, main page]

SG10201510800PA - Purification of flaviviruses - Google Patents

Purification of flaviviruses

Info

Publication number
SG10201510800PA
SG10201510800PA SG10201510800PA SG10201510800PA SG10201510800PA SG 10201510800P A SG10201510800P A SG 10201510800PA SG 10201510800P A SG10201510800P A SG 10201510800PA SG 10201510800P A SG10201510800P A SG 10201510800PA SG 10201510800P A SG10201510800P A SG 10201510800PA
Authority
SG
Singapore
Prior art keywords
flaviviruses
purification
Prior art date
Application number
SG10201510800PA
Inventor
Sophia Mundle
Stephen Anderson
Original Assignee
Sanofi Pasteur Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Llc filed Critical Sanofi Pasteur Biologics Llc
Publication of SG10201510800PA publication Critical patent/SG10201510800PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201510800PA 2012-01-09 2013-01-08 Purification of flaviviruses SG10201510800PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261584461P 2012-01-09 2012-01-09

Publications (1)

Publication Number Publication Date
SG10201510800PA true SG10201510800PA (en) 2016-01-28

Family

ID=48781838

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201510800PA SG10201510800PA (en) 2012-01-09 2013-01-08 Purification of flaviviruses
SG11201403891SA SG11201403891SA (en) 2012-01-09 2013-01-08 Purification of flaviviruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201403891SA SG11201403891SA (en) 2012-01-09 2013-01-08 Purification of flaviviruses

Country Status (6)

Country Link
US (1) US20150030565A1 (en)
EP (1) EP2802650A4 (en)
AU (1) AU2013208187B2 (en)
CA (1) CA2896931A1 (en)
SG (2) SG10201510800PA (en)
WO (1) WO2013106337A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195453A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
WO2015195452A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Single-pass filtration systems and processes
CN106132517B (en) 2014-06-25 2019-12-13 Emd 密理博公司 Filter elements, tangential flow filtration systems, liquid filtration processes
SG10202006102UA (en) 2014-08-29 2020-07-29 Emd Millipore Corp Processes For Filtering Liquids Using Single Pass Tangential Flow Filtration Systems AndTangential Flow Filtration Systems With Recirculation of Retentate
SG10201901555UA (en) 2014-08-29 2019-03-28 Emd Millipore Corp Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate
EP3353193A4 (en) * 2015-09-22 2019-04-03 Sanofi Pasteur Biologics, LLC PURIFICATION OF SYNCYTIAL RESPIRATORY VIRUS
EP3468698B1 (en) 2016-06-09 2022-06-29 EMD Millipore Corporation Radial-path filter elements, systems and methods of using same
PE20210106A1 (en) * 2017-10-16 2021-01-19 Serum Institute Of India Pvt Ltd STABLE VACCINE COMPOSITIONS THAT INCLUDE INTER ALIA A RECOMBINANT LIVE ATTENUATED FLAVIVIRUS AND PROCESS FOR THE PREPARATION OF THE SAME
US11999975B2 (en) * 2018-07-04 2024-06-04 Probiogen Ag Method for purifying an enveloped virus
BR112022015710A2 (en) * 2020-02-27 2022-09-27 Takeda Vaccines Inc METHOD TO REMOVE HOST CELL DNA FROM VIRUS PREPARATION
GB202215814D0 (en) * 2022-10-26 2022-12-07 Cytiva Bioprocess R & D Ab A chromatography device, system, and use thereof for analytic separation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889632A (en) 1987-12-10 1989-12-26 Ceskoslovenska Akademie Ved Macroporous polymeric membranes for the separation of polymers and a method of their application
ATE200303T1 (en) 1994-08-23 2001-04-15 Bia Separations Doo METHOD AND DEVICE FOR THE RAPID SEPARATION AND/OR CONVERSION OF SUBSTRATES
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US6207439B1 (en) * 1997-03-25 2001-03-27 Center For Disease Control Purification of Japanese encephalitis virus
JP4109418B2 (en) 1998-02-27 2008-07-02 ビーアイエー セパレイションズ ディーオーオー New chromatography equipment
WO2002000337A1 (en) 2000-06-27 2002-01-03 Bia Separations D.O.O. A chromatography material and a process of manufacturing that material
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
RU2465326C2 (en) * 2005-04-24 2012-10-27 Санофи Пастер Байолоджикс Ко Recombinant flaviviral vaccines
WO2006122964A1 (en) 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
MY151062A (en) * 2006-02-27 2014-03-31 Univ Texas Pseudoinfectious flavivirus and uses thereof
EP1878791A1 (en) * 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
US20100184832A1 (en) 2006-07-14 2010-07-22 Sanofi Pasteur Biologics Co. Construction of Recombinant Virus Vaccines by Direct Transposon-Mediated Insertion of Foreign Immunologic Determinants into Vector Virus Proteins
US8486417B2 (en) * 2007-01-31 2013-07-16 Sanofi Pasteur Biologics, Llc Recombinant bicistronic Flavivirus vectors
US8815564B2 (en) * 2008-03-14 2014-08-26 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
WO2010107847A1 (en) 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
US20110142863A1 (en) * 2009-12-16 2011-06-16 Millipore Corporation Flow through purification processes for large biomolecules

Also Published As

Publication number Publication date
US20150030565A1 (en) 2015-01-29
AU2013208187A1 (en) 2014-07-24
WO2013106337A1 (en) 2013-07-18
AU2013208187B2 (en) 2018-07-12
SG11201403891SA (en) 2014-08-28
CA2896931A1 (en) 2013-07-18
EP2802650A4 (en) 2015-09-30
EP2802650A1 (en) 2014-11-19

Similar Documents

Publication Publication Date Title
IL287057A (en) Purification of iduronate-2 sulfatase
IL237604A0 (en) Formulations of enzalutamide
SG10201510800PA (en) Purification of flaviviruses
ZA201406082B (en) Use of ccr3-inhibitors
GB201513279D0 (en) Micro-evolution of microbes
IL263162B (en) Purification of cystathionine beta-synthase
EP2800747A4 (en) Polymorphs of perampanel
SG11201406800UA (en) Purification of air
GB201501016D0 (en) Preparation of 18F-fluciclovine
IL237862A0 (en) Methods of reducing scalant formation
PL2888228T3 (en) Inhibitors of cd40-traf6 interaction
GB201215942D0 (en) Method of treatent
SG11201504201RA (en) Purification of x-ray contrast agents
GB201207907D0 (en) Treatment of depression
PL2924188T3 (en) Set of construction plates
TWM433525U (en) Structure of calorifier
IL233740A0 (en) Treatment of liver conditions
IL233446A0 (en) Polymorphs of perampanel
GB201217666D0 (en) Construction of surfaces
GB201212717D0 (en) Treatment of musculoskeletal conditions
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment